Background:
Decreases in extracellular adenosine (ADO) production are associated with increased inflammation and immune activation in ART-treated people living with HIV (PWH). We previously showed that 12 weeks (w) of treatment with dipyridamole (DP), which increases extracellular ADO levels, decreased CD8+ T cell activation in PWH. Here, we investigated if the decrease in activation also affected HIV-specific T cell responses.
Methods:
PWH with viral suppression on ART were randomized to 12w of DP vs placebo (PL). Peripheral blood mononuclear cells were obtained pre- and post- DP treatment. Using flow cytometry, we evaluated changes in Gag- and Env-specific polyfunctional T cell responses (CD107a, TNFα, IFNγ, IL2, Granzyme B). We measured purine levels, soluble markers of inflammation, T cell immune activation (HLA-DR/CD38+) and cell cycling (Ki-67), and residual viremia by single copy assay to determine whether immune responses were associated with these parameters (using Spearman).
Results:
Twenty of 40 participants enrolled (9 DP, 11 PL) had available specimens for this substudy (90% male; median age 57; median CD4+ 673 cells/mL; median 17 years on ART). There was a significant decrease in Gag-specific (% change from baseline (BL) to w12 -63.18% DP vs -28.14 PL; p< 0.001; Mann Whitney) and Env-specific (-57.5% DP vs -16.0% PL; p=0.025) CD4+ polyfunctional response (2 or more immune mediators expressed). No differences in HIV-specific CD8+ T cell responses were observed. Higher levels of inosine, a surrogate of ADO, at w 12 was associated with decreased CD4+ Gag-specific polyfunctional responses at w12 compared to BL (r= -0.56; p=0.04). Although there were no overall differences in BL to w 12 changes in cell cycling, change in the frequency of CD4+ and CD8+ cell cycling positively correlated with change in Gag-specific CD4+ polyfunctional responses and Env-specific CD8+ polyfunctional responses, respectively (r=0.52, p=0.01 and r= 0.55; p=0.01). There were no associations between HIV-specific polyfunctional T cell and frequencies of activated T cells, levels of soluble inflammatory markers or residual viremia.
Conclusions:
Increases in ADO production following treatment with DP were associated with reductions in HIV-specific CD4+ T-cell responses in this substudy. Although the clinical implications of this finding are unknown, trials of interventions targeting immune activation in PWH should evaluate their impact on HIV-specific immune responses.